Peroxisome Proliferator-Activated Receptor-Gamma Activation in Peritoneal Dialysis Patients (PPAR)
Targeting Peroxisome Proliferator-Activated Receptor-Gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? (PROOF Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong, 0000
- Queen Mary Hospital, Tung Wah Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Both prevalent patients or patients newly started on continuous peritoneal dialysis, with or without diabetes mellitus will be considered eligible for study entry.
- For patients newly started on chronic peritoneal dialysis, they will be suitable for recruitment into the study after one month on peritoneal dialysis.
- Patients who provide informed consent for the study
Exclusion Criteria:
- Patients with underlying active malignancy
- Patients with chronic liver disease or liver cirrhosis
- Patients with active infections
- Patients with other chronic active inflammatory disease such as systemic lupus erythematosus, rheumatoid arthritis
- Patients who refuse study participation
- Patients with underlying congenital heart disease or rheumatic heart disease
- Patients with poor general condition
- Patients with plans for living related kidney transplant within 2 years
- Female patients with pregnancy
- Patients with history of recurrent hypoglycemia
- Patients with Class III and IV congestive heart failure
- Patients already receiving glitazones treatment at the screening visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Active intervention arm
Peroxisome proliferator activator receptor gamma treatment, Pioglitazone
|
pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
Other Names:
|
|
Placebo Comparator: placebo pill
placebo comparator
|
1 capsule daily, 96 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in carotid intima-media thickness
Time Frame: over 48 weeks
|
Change in carotid intima-media thickness
|
over 48 weeks
|
|
change in flow mediated dilatation (marker of endothelial function)
Time Frame: over 48 weeks
|
change in flow mediated dilatation (marker of endothelial function)
|
over 48 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in aortic pulse wave velocity
Time Frame: over 96 weeks
|
change in aortic pulse wave velocity
|
over 96 weeks
|
|
change in augmentation index-heart rate adjusted
Time Frame: over 96 weeks
|
change in augmentation index-heart rate adjusted
|
over 96 weeks
|
|
change in nitroglycerin-mediated dilatation
Time Frame: over 48 weeks
|
change in nitroglycerin-mediated dilatation
|
over 48 weeks
|
|
change in coronary artery calcium score
Time Frame: over 96 weeks
|
change in coronary artery calcium score
|
over 96 weeks
|
|
change in heart valves calcium score
Time Frame: over 96 weeks
|
change in heart valves calcium score
|
over 96 weeks
|
|
change in carotid artery calcium score
Time Frame: over 96 weeks
|
change in carotid artery calcium score
|
over 96 weeks
|
|
change in abdominal visceral fat
Time Frame: over 96 weeks
|
change in abdominal visceral fat
|
over 96 weeks
|
|
change in subcutaneous fat
Time Frame: over 96 weeks
|
change in subcutaneous fat
|
over 96 weeks
|
|
change in blood pressure
Time Frame: over 96 weeks
|
change in blood pressure
|
over 96 weeks
|
|
change in C-reactive protein
Time Frame: over 96 weeks
|
change in C-reactive protein
|
over 96 weeks
|
|
change in residual kidney function
Time Frame: over 96 weeks
|
change in residual kidney function
|
over 96 weeks
|
|
change in HOMA index (among those not on insulin)
Time Frame: over 96 weeks
|
Change in insulin resistance index
|
over 96 weeks
|
|
change in D/P creatinine ratio
Time Frame: over 96 weeks
|
Change in peritoneal solute transport parameter
|
over 96 weeks
|
|
change in peritoneal ultrafiltration with 2.5% during PET
Time Frame: over 96 weeks
|
Change in peritoneal ultrafiltration volume
|
over 96 weeks
|
|
change in handgrip strength
Time Frame: over 96 weeks
|
change in handgrip strength
|
over 96 weeks
|
|
Change in cardiac biomarkers
Time Frame: over 96 weeks
|
change in cardiac biomarkers
|
over 96 weeks
|
|
change in insulin dose (among those on insulin)
Time Frame: over 96 weeks
|
change in insulin dose
|
over 96 weeks
|
|
change in endothelial progenitor cells
Time Frame: over 96 weeks
|
change in endothelial progenitor cells
|
over 96 weeks
|
|
change in central systolic blood pressure
Time Frame: over 96 weeks
|
change in central systolic blood pressure
|
over 96 weeks
|
|
Change in central diastolic blood pressure
Time Frame: over 96 weeks
|
change in central diastolic blood pressure
|
over 96 weeks
|
|
change in glycemic control (fasting glucose, and glycosylated hemoglobin)
Time Frame: over 96 weeks
|
change in glycemic control
|
over 96 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
overall survival
Time Frame: over 96 weeks
|
Hard outcome
|
over 96 weeks
|
|
major adverse cardiovascular event-free survival
Time Frame: over 96 weeks
|
hard outcome
|
over 96 weeks
|
|
Fluid overload/heart failure event-free survival
Time Frame: over 96 weeks
|
hard outcome
|
over 96 weeks
|
|
myocardial infarction event-free survival
Time Frame: over 96 weeks
|
hard outcome
|
over 96 weeks
|
|
3 point major adverse cardiovascular event-free survival
Time Frame: over 96 weeks
|
Hard outcome
|
over 96 weeks
|
|
4 point major adverse cardiovascular event-free survival
Time Frame: over 96 weeks
|
Hard outcome
|
over 96 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Angela YM Wang, MD, PhD, FRCP, University of Hong Kong, Queen Mary Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A111-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.